31 results about "Lipid storage" patented technology

The present invention is based on the discovery of a set of genes that are involved in lipid-droplet formation and regulation. Accordingly, the present invention provides methods of increasing or decreasing lipid concentrations in eukaryotic cells by decreasing or increasing expression of one of these genes. Increased lipid concentrations may be useful, for example, in the generation of biofuels. Decreased lipid concentration may be useful in the treatment of diseases characterized by excessive lipid storage. In addition, the invention provides methods of identifying markers of diseases characterized by excessive lipid storage.

An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.

An orally or parenterally administered composition for reducing the storage of lipids in a human, the composition comprising: an effective amount of hydroxycitric acid; an effective amount of carnitine; an effective amount of biotin; an effective amount of one or more gluconeogenic substrates selected from the group consisting of: aspartate, lactate, glycerol, and a gluconeogenic amino acid or alphaketo analogue thereof; an effective amount of eicosapentanoic acid; and an effective amount of one or more ingredients selected from the group consisting of: medium chain triglycerides (MCT) with fatty acid backbones containing 6 to 14 carbon atoms or their individual fatty acid analogues or metabolic precursors, sesame seeds or derivative products, sesamin and/or its epimer episesamin, caffeine, forskolin, 7-keto dehydroepiandrosterone (7-keto DHEA), green tea extract containing epigallocatechingallate (EGCG), capsaicum, and 5-hydroxytryptophan (5-HTP). The supplement may also be combined with a food, beverage, condiment, spice or salad dressing base to provide a food, beverage, condiment, spice or salad dressing product designed to reduce lipid storage.

The present invention provides pharmaceutical compositions, methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concentration, for example, hypercholesterolemia, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, cholesterol gallstones, and lipid storage diseases. The compositions, methods, combinations, and kits of the present invention are pharmaceutical compositions comprising atherapeutically effective amount of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, and compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate. A typical pharmaceutical composition of the invention contains and effective amount of atorvastatin and an effective amount of policosanol.

This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.

The invention relates to a super-high-efficiency lipid hydrolysis reactor which comprises a raw material lipid storage tank, a water storage tank, a steam inlet tube, a gas-liquid ejection mixer, an inner cylinder, an outer cylinder, a glycerinum flash tank, a fatty acid flash tank, a scraper evaporator, a glycerinum rectifying column and a fatty acid rectifying tower. A high-temperature high-pressure steam power source is adopted, and a gas-liquid ejection mixer is taken as a compulsive material mixing, mass transfer and reaction key component. The invention further provides a reaction process of the reactor. By adopting the reactor, the phase boundary of lipid and water is greatly increased, so that the reaction time of hydrolysis is greatly shortened, on the basis, the reaction temperature and the pressure can be appropriately reduced, so that the energy consumption and the operation cost are reduced, and meanwhile the security coefficient of equipment is increased; the reactor can be used in the hydrolysis process of lipid consisting of different fatty acids, the different fatty acids and glycerinum water can be efficiently separated after the hydrolysis is completed, and a corresponding fatty acid product and a glycerinum product are obtained.

The composition of the present invention comprises (1) a biologically effective amount of an extract of a plant of the genus Eucalyptus as an active ingredient, and (2) a biologically acceptable carrier or diluent, and is effective for inhibiting or preventing obesity (increase in weight), lipid storage disease, hyperlipemia, arteriosclerosis, or thrombosis, and is also effective for inhibiting or reducing an amount of triglyceride or an amount of cholesterol in blood. Therefore, the composition of the present invention is used in the form of drugs, food products, food additives, animal feeds, and additives for animal feeds.

The present disclosure relates to polymers comprising conjugates of cyclodextrin or derivatives thereof and a linker moiety, and their application in treating lipid storage disorders by the removal of lipids such as cholesterol from cells. The polymers having the following structure: Formula (I), wherein CD, L, and n are defined herein, exhibit improved properties including but not limited to improved biocompatibility, improved retention time, prolonged duration of action in cells, and increased efficacy in treating a variety of kidney diseases and associated conditions.

Methods and compositions are provided for the prevention and/or treatment of symptoms associated with lipid accumulation disorders caused by attenuated leptin activity and by lipid storage disorders. The methods involve administering at least one oxygenated cholesterol sulfate (OCS) to a subject with the disorder. The disorder may be acquired or congenital (hereditary).

The invention provides novel compounds of Formulas (I)-(IV), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C.

The invention discloses an oil-resistant saccharomyces cerevisiae genetically engineered bacterium and a construction method thereof, and belongs to the technical field of bioengineering. The invention discloses a saccharomyces cerevisiae genetically engineered bacterium capable of overexpressing Are2 and Yft2 genes and replacing SEI1 and Tgl1 genes at the same time. The saccharomyces cerevisiae is modified by replacing genes with original saccharomyces cerevisiae by using a homologous recombination technology. The amount of sterol substances stored in the original strain BY4741 is limited, and excessive accumulated lipid intermediates can generate a product inhibition effect, so that synthesis of a target product is directly influenced, cytotoxicity can be caused, and cell viability can be reduced. Compared with an original starting strain, the modified oil-resistant saccharomyces cerevisiae genetically engineered bacterium has the advantages that the volume ratio of a lipid droplet structure of a cell lipid storage unit is remarkably increased, the cytotoxicity and product inhibition caused by lipid accumulation are effectively reduced, and the intracellular cumulant of ester compounds is remarkably increased; and a new strategy and a good tolerant cell model are provided for breaking through the de novo synthesis limit of the ester compound saccharomyces cerevisiae.

Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin α4β1, Very Late Antigen-4 positive neural precursor cell (“VLA4+ NPC”) transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson's disease (PD), Dementia with Lewy bodies.